Advances in Biopharmaceuticals and Biotechnology

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across biopharmaceuticals and biotechnology. Diverse innovations in biologics production, drug development, and diagnostics are illustrated. The corresponding clinical validation scenario focused on urinary incontinence is depicted along with industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellu

Table of Contents

Advances in Biopharmaceuticals and BiotechnologyInnovations Biologics Production, Drug Development, and Diagnostics Lipid Lowering Agents Could Aid in Cardiovascular Treatment Novel Cellular Therapy Targeting Niche Disease Segments Single Use Bioreactors Actively Used for Biologics Production Diagnostic Solutions for Acute Myeloid Leukemia Clinical Trials and Industry InteractionsClinical Trials by Region and Phase for Urinary IncontinenceIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.